Peapack Gladstone Financial Corp Purchases 2,314 Shares of Danaher Co. (NYSE:DHR)

Peapack Gladstone Financial Corp grew its position in Danaher Co. (NYSE:DHR) by 2.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 106,616 shares of the conglomerate’s stock after acquiring an additional 2,314 shares during the quarter. Peapack Gladstone Financial Corp’s holdings in Danaher were worth $29,641,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in Danaher in the 2nd quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher during the 2nd quarter valued at approximately $25,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher during the 3rd quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher during the 3rd quarter valued at approximately $40,000. Finally, FSA Wealth Management LLC bought a new position in shares of Danaher during the 3rd quarter valued at approximately $50,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR stock opened at $234.50 on Friday. Danaher Co. has a twelve month low of $219.15 and a twelve month high of $281.70. The stock has a market capitalization of $169.37 billion, a price-to-earnings ratio of 44.75, a P/E/G ratio of 4.33 and a beta of 0.83. The stock has a fifty day simple moving average of $247.62 and a two-hundred day simple moving average of $257.62. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.02 EPS. On average, analysts predict that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on DHR. Stifel Nicolaus boosted their target price on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. KeyCorp boosted their target price on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Robert W. Baird cut their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Evercore ISI boosted their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, Wells Fargo & Company started coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.